OneThree’s Workflow to ID Synergistic Drug Combos

OneThree’s Workflow for Identifying Synergistic Drug Combinations Background OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was builtin a lab setting; allowing us to engineer our methodologies around real-world results. […]

OneThree’s Workflow for Target and Compound Discovery

OneThree’s Workflow for Target and Compound Discovery Background OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was builtin a lab setting; allowing us to engineer our methodologies around real-world results. […]

OneThree’s Workflow for Predicting Drug Toxicity

OneThree’s Workflow for Predicting Drug Toxicity Background OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was builtin a lab setting; allowing us to engineer our methodologies around real-world results. While […]

Identifying the Mechanism and New Indications for ONC201

Identifying the Mechanism and New Indications for ONC201 Background OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was built in a lab setting; allowing us to engineer our methodologies around […]

OneThree’s Workflow for Biomarker and Indication Selection

OneThree’s Workflow for Biomarker and Indication Selection Background OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was built in a lab setting; allowing us to engineer our methodologies around real-world […]

Repositioning Approved Drugs as Combinations for MT Resistance

Repositioning Approved Drugs as Combinations for MT Resistance (This post relates to work done at Weill Cornell, where OneThree’s core technology was developed) This project is a bit of a followup from our previous collaboration with the Giannakakou lab where we identified and validated novel candidates that could act on cancer cells resistant to one […]

Predicting Genotype Specific Synergistic Combinations

Predicting Genotype Specific Synergistic Combinations (Before jumping in, I want to give a shout out to Coryandar Gilvary, a current graduate student at Weill Cornell. She led the work and was lead author on this method and is one of the best scientists working on machine learning for drug development I’ve met. This post relates […]

Discovery of Novel Microtubule inhibitors

Discovery of Novel Microtubule inhibitors (This post relates to work done at Weill Cornell University, where OneThree’s core technology was developed) Proper function of microtubules is essential to any cell, especially cancer cells which rely on high growth rates. Because of this, one of the most-used classes of cancer therapeutics are drugs that inhibit the […]